AiM Medical Robotics Raises $3.4m in Seed Financing to Advance Neurosurgery with MRI-Compatible Robotics

FORT LAUDERDALE, Fla., March 15, 2022 – AiM Medical Robotics, a leading developer of MRI-compatible intraoperative robotics for neurosurgery, today announced that it has raised $3.4 million in seed funding led by IQ Capital and Surrey Capital Partners.

AiM will use the capital to accelerate the development of its industry-first MRI-compatible robotics platform, which is designed to improve outcomes for patients undergoing neurosurgery and provide cost savings to hospitals by eliminating errors and reducing procedure times. The company will also continue to grow its team across research, engineering, and clinical and medical affairs.

Traditional approaches in robot-assisted surgery can be expensive, incompatible with existing surgical workflows, and incapable of meaningfully improving patient outcomes. AiM’s platform is designed to be cost-efficient, streamlined, and differentiated in its ability to help improve outcomes for patient undergoing neurosurgery for functional brain disorders (Parkinson’s, Epilepsy, etc.) and cancer.

Other investors in the round include The Lambda Fund, a part of the Lamport Family Office, Triple Ring Technologies, and Worcester Polytechnic Institute (WPI), amongst additional inside investors. As of the close, Samantha Surrey, Founder of Surrey Capital Partners, has joined AiM’s Board of Directors.

“AiM is on an exciting journey to develop and commercialize an industry-first in robot-assisted surgery with our MRI-compatible robotics platform” said Bob Cathcart, CEO of AiM. “I am honored to have the support of our investors as we continue building our team of experts in robotics and medicine, and as we work towards our north star of improving patient outcomes in neurosurgery.” 

“AiM is bringing together best-in-class robotics and deep clinical expertise to develop what will be a game changing robot-assisted surgery platform for surgeons and patients” said Samantha Surrey, Founder of Surrey Capital Partners. “I am thrilled to participate in AiM’s financing round and to work with fellow members of AiM’s Board of Directors to support their team.”

“AiM’s groundbreaking technology has the potential to transform surgery as we know it, to the great benefit of patients globally” said Ed Stacey, Managing Partner at IQ Capital. “Built on over a decade of academic research and development, AiM’s MRI-compatible robotics platform opens the door to unprecedented levels of surgical precision and novel categories of surgical procedures. We are delighted to be supporting AiM’s truly outstanding team.”

In March 2022, AiM announced that it had appointed Dr. Jonathan Sackier as its Chief Medical Officer (CMO). The news came on the heels of AiM’s announcement that Gregory Cole, Ph.D. had been appointed as its Chief Technology Officer (CTO). The company was selected as a Featured Innovator at the Life Science Intelligence Emerging MedTech Summit 2022 and will be presenting at the event which takes place March 15^th to March 18^th in Dana Point, CA.